Tonix Pharmaceuticals Hol... (TNXP)
Tonix Pharmaceuticals Statistics
Share Statistics
Tonix Pharmaceuticals has 6.88M shares outstanding. The number of shares has increased by 2964.8% in one year.
Shares Outstanding | 6.88M |
Shares Change (YoY) | 2964.8% |
Shares Change (QoQ) | 14.77% |
Owned by Institutions (%) | 0% |
Shares Floating | 6.88M |
Failed to Deliver (FTD) Shares | 445 |
FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 919.91K, so 14.3% of the outstanding shares have been sold short.
Short Interest | 919.91K |
Short % of Shares Out | 14.3% |
Short % of Float | 14.3% |
Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.19 and the forward PE ratio is -3.63. Tonix Pharmaceuticals's PEG ratio is 0.01.
PE Ratio | -0.19 |
Forward PE | -3.63 |
PS Ratio | 2.41 |
Forward PS | 0.2 |
PB Ratio | 0.17 |
P/FCF Ratio | -0.4 |
PEG Ratio | 0.01 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tonix Pharmaceuticals.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.5, with a Debt / Equity ratio of 0.06.
Current Ratio | 6.5 |
Quick Ratio | 6.04 |
Debt / Equity | 0.06 |
Debt / EBITDA | -0.11 |
Debt / FCF | -0.13 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $124.62K |
Profits Per Employee | $-1.61M |
Employee Count | 81 |
Asset Turnover | 0.06 |
Inventory Turnover | 0.92 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -96.65% in the last 52 weeks. The beta is 1.51, so Tonix Pharmaceuticals's price volatility has been higher than the market average.
Beta | 1.51 |
52-Week Price Change | -96.65% |
50-Day Moving Average | 15.47 |
200-Day Moving Average | 25.1 |
Relative Strength Index (RSI) | 49.56 |
Average Volume (20 Days) | 1.66M |
Income Statement
In the last 12 months, Tonix Pharmaceuticals had revenue of 10.09M and earned -130.04M in profits. Earnings per share was -176.6.
Revenue | 10.09M |
Gross Profit | 2.33M |
Operating Income | -136.7M |
Net Income | -130.04M |
EBITDA | -71.73M |
EBIT | -75.15M |
Earnings Per Share (EPS) | -176.6 |
Balance Sheet
The company has 98.78M in cash and 8.12M in debt, giving a net cash position of 90.66M.
Cash & Cash Equivalents | 98.78M |
Total Debt | 8.12M |
Net Cash | 90.66M |
Retained Earnings | -730.69M |
Total Assets | 162.89M |
Working Capital | 100.69M |
Cash Flow
In the last 12 months, operating cash flow was -60.92M and capital expenditures -120K, giving a free cash flow of -61.05M.
Operating Cash Flow | -60.92M |
Capital Expenditures | -120K |
Free Cash Flow | -61.05M |
FCF Per Share | -82.9 |
Margins
Gross margin is 23.07%, with operating and profit margins of -1354.28% and -1288.25%.
Gross Margin | 23.07% |
Operating Margin | -1354.28% |
Pretax Margin | -1288.25% |
Profit Margin | -1288.25% |
EBITDA Margin | -710.61% |
EBIT Margin | -1354.28% |
FCF Margin | -604.77% |
Dividends & Yields
TNXP does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for TNXP is $585, which is 3309.1% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $585 |
Price Target Difference | 3309.1% |
Analyst Consensus | Strong Buy |
Analyst Count | 2 |
Stock Splits
The last stock split was on Feb 5, 2025. It was a backward split with a ratio of 1:100.
Last Split Date | Feb 5, 2025 |
Split Type | backward |
Split Ratio | 1:100 |
Scores
Altman Z-Score | -4.41 |
Piotroski F-Score | 5 |